t.spot covid
avitag biotin blocking cell proliferation reagent wst 1 ctgf elisa novex gel pcr machines Product tbr2 antibody western blot control

t.spot covid

HIGHLIGHTS

  • TSPOT.COVID is an ELISpot interferon gamma-release assay for SARS-CoV-2
  • TSPOT.COVID identifies a T cell response to SARS-CoV-2 spike S1 and N peptides
  • 2–8 weeks post SARS-CoV-2 diagnosis TSPOT.COVID detected 98% of infections
  • In comparison, immunoglobulin G (IgG) serology detected 83% of infections in the same period
  • Cellular immune response activated sooner and lasted longer than antibodies

Abstract

Objective

To evaluate the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in participants with SARS-CoV-2 infection.

Methods

The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 and nucleocapsid peptides. T-SPOT.COVID and anti-N immunoglobulin (Ig) G serology tests were performed on blood from 186 patients with nucleic acid amplification test (NAAT)-confirmed-SARS-CoV-2 infection and 100 control group participants.

Results

In the 2–8 weeks after NAAT-diagnosed SARS-CoV-2 infection, the T-SPOT.COVID test detected 98.4% (63 of 64) of infected participants, while anti-N IgG serology detected 82.8%. In the first 2 weeks after diagnosis, during adaptive immune response activation, there were less reactive T-SPOT.COVID responses (75.7%, 28 of 37 infected participants) and many less seropositive responses (32.4%). Response numbers tapered after 8 weeks; however, T-SPOT.COVID test continued to detect most participants with confirmed infection (83.6%, 56 of 67) and continued to out-perform serology (52.2%). T-SPOT.COVID response due to cross-reactive T cells was ruled out by demonstrating that, of 44 control group participants with T cells responsive to 4 human common cold coronavirus peptides, only 1 was T-SPOT.COVID reactive.

Conclusion

The T-SPOT.COVID test performed well in detecting SARS-CoV-2-sensitized T-cells over many months

Introduction

Long-term protection from infectious agents, such as the SARS-CoV-2 virus, is mediated by T cells and antibody-mediated immunity of the adaptive immune system (

Sette and Crotty, 2021

). The T-SPOT.COVID test was developed to identify the presence of SARS-CoV-2-responsive T cells.

T cells contribute to the understanding of SARS-CoV-2 infections in many ways. T cells can identify past SARS-CoV-2 infections at a time when PCR tests would be negative and antibodies levels may be waning (

Dan et al., 2021

;

Gudbjartsson et al., 2020

;

Poland et al., 2020

). T cells can provide immune memory lasting for months (

Dan et al., 2021

) and perhaps years, as suggested by the discovery of T cells to the SARS-CoV-1 coronavirus 17 years after infection (

Le Bert et al., 2020

). T cells may act independently of antibodies to control a SARS-CoV-2 infection, as shown by the recovery of COVID-19 patients who lack detectable antibodies but have SARS-CoV-2-responsive T cells (

Gallais et al., 2021

;

Sekine et al., 2020

). T cells also show reactivity to numerous SARS-CoV-2 epitopes, so have the potential to protect against many SARS-CoV-2 variants (

Grifoni et al., 2020

;

Tarke et al., 2021

). T cell-based assays can probe the longevity of an immune response following a SARS-CoV-2 infection or vaccination (

Goletti et al., 2021

;

Liu et al., 2021

;

Reynolds et al., 2021

). These various roles suggest that a T cell assay can be a key contributor to SARS-CoV-2 investigations.

The T-SPOT.COVID test, an enzyme-linked immunospot (ELISpot) assay, identifies T cells in peripheral blood that release interferon-gamma (IFN-γ) in response to stimulation with SARS-CoV-2 peptides. The T-SPOT.COVID test builds on the T-SPOT platform (Oxford Immunotec) used worldwide for tuberculosis and cytomegalovirus testing and the research version, the T-SPOT Discovery SARS-CoV-2 test (

Liu et al., 2021

;

t.spot covid
t.spot covid
Wyllie et al., 2021

). The T-SPOT.COVID ELISpot methodology is performed in many laboratories and offers a standardized comparison of T cell immunity among participants. In addition, ELISpot assays normalize the number of peripheral blood mononuclear cells (PBMCs), thus maintaining test effectiveness in participants with lymphopenia, a commonly reported condition in many COVID-19 patients (

Altmann and Boyton, 2020

) and immunosuppressed people.

The objective of this study was to evaluate the ability of the T-SPOT.COVID test to detect T cell responses in participants with or without a history of SARS-CoV-2 infection and to compare the T-SPOT.COVID test results with anti-N immunoglobulin (Ig)G serology results in the first several months after infection.

Materials and Methods

2.1 Participant recruitment

Participants for this single-center, cross-sectional study were recruited from patients who had attended the outpatient Primacare medical center in Fall River, Massachusetts, USA, between November 30, 2020, and March 24, 2021, a time of high demand for COVID-19 testing. Among other healthcare services, Primacare provided COVID-19 testing to anyone wanting or required to be tested. The New England Center for Clinical Research (NECCR) invited participants to join the study if they had received a positive SARS-CoV-2 nucleic acid amplification test (NAAT) at Primacare or if NECCR deemed them to be at low risk of SARS-CoV-2 infection. As this study was run independently from the participants’ healthcare providers, clinical data such as chest x-rays and hospitalizations records were not obtained. Informed consent and study approval were obtained from the Advarra institutional review board by NECCR at Primacare.
Confirmed-infection group: A NAAT, which detects the presence of the SARS-CoV-2 virus, was used to identify people infected with SARS-CoV-2 at the time of testing (

Rai et al., 2021

). Participants in the confirmed-infection group were recruited from asymptomatic and symptomatic patients who had had a positive SARS-CoV-2 NAAT result within the past 9 months. The date of the first positive NAAT result was considered the date of diagnosis of SARS-CoV-2 infection. Blood was drawn for Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) anti-N IgG serology and T-SPOT.COVID tests between 0 to 249 days after diagnosis.

The analysis of responses was divided into 3 time periods: 0 to 2 weeks after diagnosis (0 to 14 days); 2+ to 8 weeks after diagnosis (15 to 56 days); and 8+ weeks after diagnosis (57+ days).
Control group: Many SARS-CoV-2 studies use frozen pre-pandemic blood for control samples; however, the T-SPOT platform requires fresh blood to ensure consistent results. Therefore fresh blood was obtained from control group participants prospectively recruited from individuals with low risk of prior SARS-CoV-2 infection. Requirements for enrollment included no current or prior signs or symptoms of COVID-19, no known contact with a confirmed SARS-CoV-2-infected individual, no prior history of a positive SARS-CoV-2 NAAT, no SARS-CoV-2 vaccination, and no prior diagnosis with SARS-CoV-1 or Middle Eastern Respiratory Syndrome (MERS). In addition, the BIOHIT HealthCare SARS-CoV-2 lateral flow anti-N IgM/IgG serology test was performed at enrollment, and the 1 person with a positive BIOHIT result was not enrolled. Blood was drawn at enrollment for testing with T-SPOT.COVID and the Abbott CMIA anti-N IgG serology test and anyone with a positive serology result was excluded from the control group.

2.2 T-SPOT.COVID test

The T-SPOT.COVID test includes over 250 SARS-CoV-2 peptides (15-mer peptides overlapping by 11 amino acids) in 2 antigen peptide pools; one pool contains peptides from the spike S1 protein, including the receptor-binding domain, and the other contains peptides from the nucleocapsid protein.
Blood samples for the T-SPOT.COVID test were processed and analyzed according to the manufacturer’s instructions. Briefly, blood samples were drawn into lithium heparin tubes which were shipped overnight to Oxford Immunotec (Abingdon, UK) in temperature-controlled shipping boxes. Next, the T-Cell Xtend reagent (Oxford Immunotec) was added to the samples, and PBMCs were isolated by density gradient centrifugation, washed, counted, and 250 000 cells/well were plated into 4 wells of a 96-well plate.

COVID-19 Spike Antigen

30-2018 1 mg
EUR 400
Description: COVID-19 Spike recombinant antigen

COVID-19 Spike Antigen

30-2019 1 mg
EUR 400
Description: COVID-19 Spike recombinant antigen

SARS & COVID-19 coronavirus

3862 each
EUR 330
Description: nucleoprotein

SARS & COVID-19 coronavirus

3863 each
EUR 330
Description: nucleoprotein

SARS & COVID-19 coronavirus

3864 each
EUR 330
Description: nucleoprotein

COVID-19 S Protein / (GFP)– (6His) VLP COVID-19 S Protein / (GFP)– (6His) VLP

VLP001 1x108 VP/ml x 200ul
EUR 455
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with GFP genomic material. Particles were concentrated and provided in PBS solution

COVID-19 Nucleocapsid protein

30-2005 1 mg
EUR 700
Description: COVID-19 Nucleocapsid protein recombinant antigen

COVID-19 Nucleocapsid protein

30-2006 1 mg
EUR 700
Description: COVID-19 Nucleocapsid protein recombinant Antigen

COVID-19 Nucleocapsid antigen

30-2020 1 mg
EUR 400
Description: COVID-19 Nucleocapsid recombinant protein

COVID-19 Nucleocapsid antigen

30-2021 1 mg
EUR 400
Description: COVID-19 Nucleocapsid recombinant protein

STAT-NAT COVID-19 B

BSV-qPCR-12 24 tests
EUR 316
Description: STAT-NAT COVID-19 B

STAT-NAT COVID-19 HK

BSV-qPCR-13 24 tests
EUR 316
Description: STAT-NAT COVID-19 HK

COVID-19 Nucleoprotein antibody

10-2890 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

COVID-19 Nucleoprotein antibody

10-2891 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

COVID-19 Nucleoprotein antibody

10-2894 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

STAT-NAT COVID-19 MULTI

BSV-qPCR-11 96 tests
EUR 758
Description: STAT-NAT COVID-19 MULTI

COVID-19 IgG & IgM antibody

GEN-50001-50tests 50 tests
EUR 388.8
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

COVID-19 Antigen Rapid Test

ICOV-802H 25 Tests
EUR 12.5

Coronavirus (COVID-19) CE IVD

PRD-Z-Path-COVID-19-CE 96 tests
EUR 2539
Description: Coronavirus (COVID-19) CE IVD

COVID-19 Antigen Detection Kit

BSV-G61RHA20 20 tests
EUR 500
Description: COVID-19 Antigen Detection Kit

COVID-19 nucleoprotein ELISA Kit

EKF60838-48T 48T
EUR 400.4

COVID-19 nucleoprotein ELISA Kit

EKF60838-5x96T 5x96T
EUR 2717

COVID-19 nucleoprotein ELISA Kit

EKF60838-96T 96T
EUR 572

COVID-19 (SARS-CoV-2) IgG

DECOV1901 96
EUR 232

COVID-19 (SARS-CoV-2) IgA

DECOV1902 96
EUR 232

Nadal COVID-19 IgG/IgM Test

BSV-243001N-10 10 tests
EUR 316
Description: Nadal COVID-19 IgG/IgM Test

COVID-19 Envelope Protein Antibody

E38PA9967 100ul
EUR 225
Description: Available in various conjugation types.

COVID-19 S Protein -(6His) VLP

VLP003 1x108 VP/ml x 200ul
EUR 455
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with Null non-sense sequence. Particles were concentrated and provided in PBS solution

COVID-19 Spike glycoprotein Antibody

E38PA9966 100ul
EUR 225
Description: Available in various conjugation types.

GA COVID-19 Rapid Antigen Test

BSV-3980 20 tests
EUR 500
Description: GA COVID-19 Rapid Antigen Test

COVID-19 Nucleocapsid Protein Antibody

E38PA9965 100ul
EUR 225
Description: Available in various conjugation types.

COVID-19 Nucleocapsid recombinant antigen

00221-V 1 MG
EUR 850

COVID-19 Nucleocapsid recombinant antigen

00221-V-100ugvial 100 ug/vial
EUR 150
Description: COVID-19 Nucleocapsid recombinant antigen

Biocredit Covid-19 Ag Detection Kit

G61RHA20 20 test cards (pkg)
EUR 114

Leave a Reply

Your email address will not be published. Required fields are marked *